Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.46 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.43 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2566337 | 0.84 | KDM4E (0.37) | LMNANPSR1TDP1AKR1C3AKR1B10 | |
| SCHEMBL16428592 | 0.81 | KDM4E (0.60) | KDM4EATMFNTAFNTB | |
| SCHEMBL18952257 | 0.80 | KDM4E (0.48) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL1135821 | 0.80 | TSHR (0.42) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL18952260 | 0.80 | KDM4E (0.48) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL16167489 | 0.80 | FNTA (0.61) | KDM4EATMFNTAFNTB | |
| SCHEMBL16428262 | 0.80 | FNTA (0.61) | KDM4EATMFNTAFNTB | |
| SCHEMBL16167488 | 0.80 | FNTA (0.61) | KDM4EATMFNTAFNTB | |
| SCHEMBL1809605 | 0.76 | TSHR (0.61) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL6142645 | 0.74 | TSHR (0.34) | TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889660-B2 | Methods for treating obesity or an obesity related condition | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130072555-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-03-21 | — | — | US | disclosed |
| US-8338394-B2 | Methods for treating metabolic diseases | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100135977-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-03 | — | — | US | disclosed |
| WO-2008063768-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072555-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | GPR119, CYP27A1, HSD17B13 | TSHR 575/4885GABRR1 2017/4885GABRR2 2157/4885 |
| US-20100135977-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | CYP27A1, HSD17B13, GPR119 | TSHR 1078/4885GABRR1 1667/4885GABRR2 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.